Pharmacological Management of Behavioral and Cognitive Symptoms in Frontotemporal Dementia (FTD)

Introduction to Management

Non-pharmacological interventions should be considered as first-line management for behavioral symptoms in frontotemporal dementia, with pharmacological treatments reserved for cases where non-pharmacological approaches are insufficient or when there is significant risk of harm 1, 2, 3

Before initiating any pharmacological treatment, investigate and treat potential underlying causes of behavioral changes (e.g., pain, urinary tract infections) in patients with frontotemporal dementia 1, 2
Screen for specific behavioral changes through interviews with the patient, family members, and healthcare team members in frontotemporal dementia patients 1
Consider using ABC (antecedent-behavior-consequences) charting approach for behavioral management in moderate to severe cases of frontotemporal dementia 2

Atypical antipsychotics should be considered only for severe behavioral symptoms with psychotic features (hallucinations and delusions) causing distress in frontotemporal dementia patients 4
Use of atypical antipsychotics should be limited to situations where there is clear and imminent risk of harm with severe and distressing symptoms in frontotemporal dementia patients 5
Monitor closely for adverse effects and consider trial dose reduction or discontinuation after symptoms stabilize in frontotemporal dementia patients on atypical antipsychotics 4

Thioridazine, chlorpromazine, or trazodone should not be used for behavioral and psychological symptoms in frontotemporal dementia patients 6
Conventional antipsychotics like haloperidol should not be used as first-line management for frontotemporal dementia patients 6

Evaluate response to pharmacological interventions within 30 days; if minimal or no improvement is observed, refer to a mental health professional for frontotemporal dementia patients 4
For patients on psychotropics, conduct close follow-up to monitor for adverse effects in frontotemporal dementia patients 5
Consider tapering or discontinuing pharmacological treatments when used only for dementia-related behavioral symptoms after 6 months of symptom stabilization in frontotemporal dementia patients 4
Regularly reassess the need for continued medication, as neuropsychiatric symptoms change and fluctuate over the course of dementia in frontotemporal dementia patients 5

Combination pharmacotherapy for severe behavioral symptoms and psychotic features can be considered after two different trials with two different classes of agents at sufficient doses in frontotemporal dementia patients 4

Relying solely on pharmacological interventions without implementing non-pharmacological strategies for frontotemporal dementia patients 7, 5
Using medications with significant anticholinergic effects, which can worsen cognitive symptoms in frontotemporal dementia patients 8
Failing to monitor for medication side effects, which can sometimes worsen behavioral symptoms in frontotemporal dementia patients 5
Not considering the risk-benefit ratio of medication use, especially given the lack of FDA approval for psychotropics in treating neuropsychiatric symptoms in frontotemporal dementia patients 5